Kingdon Capital Management, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Kingdon Capital Management, L.L.C.
- $613 Million
- Q4 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 2,000,000 shares of SNDX stock, worth $25.2 Million. This represents 4.31% of its overall portfolio holdings.
Number of Shares
2,000,000
Previous 1,000,000
100.0%
Holding current value
$25.2 Million
Previous $19.3 Million
37.35%
% of portfolio
4.31%
Previous 2.31%
Shares
4 transactions
Others Institutions Holding SNDX
# of Institutions
233Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$107 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$99.7 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$75 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$67 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$61.6 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $713M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...